The global Continuous Renal Replacement Therapy Market was worth US$ 1 Billion in the year 2021 and is poised to reach US$ 1.68 Billion by the year 2027 at a CAGR of 7.7% between 2021 and 2027.

Continuous Renal Replacement Therapy is inclusive of removal of solute from the blood through hemofiltration or hemodialysis or both combined. The therapy lasts for close to 24 hours in an Intensive Care Unit (ICU), thereby rendering it different from the other types of traditional renal replacement therapies like IHD (Intermittent Hemodialysis), which comprises 4-6 hours (at times, even less).

The key participants are into adopting technological advancements regarding acute therapy. For instance – Baxter International Inc., in the year 2019, did clear its integrated TherMax blood warmer and PrisMax system for TPE (therapeutic plasma exchange) and continuous renal replacement therapy.

Software integration is being looked upon as a novel tool for performing continuous renal replacement therapies effectively and also with utmost safety. Baxter has come up with PRISMAFLEX system to facilitate critical care. It is actually one of the flexible platforms offering personalized therapies as per the patients’ convenience. B. Braun also has its Diapact Continuous Renal Replacement Therapy (CRRT) that enables critical blood filtration.

Some of the key players featured in the report include Fresenius Medical Care AG & Co. KGaA; Baxter International Inc.; B. Braun Melsungen AG; Medica SpA; Nikkiso Co., Ltd.; Nipro corp.; Toray Medical Co., Ltd.; NxStage Medical, Inc.; Asahi Kasei Corp. and Medtronic plc.

Browse More@ https://www.futuremarketinsights.com/reports/continuous-renal-replacement-therapy-market

Segmentation

The report offers a comprehensive taxonomy of the continuous renal replacement therapy market based on product type, end user and region. Continuous renal replacement therapy is sold in two types: systems and consumables. The consumables segment covers various types of hemofilter sets, solutions and other accessories.